Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas D Penning

Showing results (11-20 of 34) with videos related to

Pageof 4
Sort By:
ACS Medicinal Chemistry Letters|January 16, 2015
Pyrimidine-based tricyclic molecules as potent and orally efficacious inhibitors of wee1 kinaseYunsong Tong, Maricel Torrent, Alan S Florjancic, et al.
Bioorganic & Medicinal Chemistry Letters|July 1, 2008
Synthesis and SAR of novel, potent and orally bioavailable benzimidazole inhibitors of poly(ADP-ribose) polymerase (PARP) with a quaternary methylene-amino substituentGui-Dong Zhu, Viraj B Gandhi, Jianchun Gong, et al.
Bioorganic & Medicinal Chemistry|July 7, 2012
Discovery and SAR of orally efficacious tetrahydropyridopyridazinone PARP inhibitors for the treatment of cancerGui-Dong Zhu, Jianchun Gong, Viraj B Gandhi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 26, 2009
ABT-888 confers broad in vivo activity in combination with temozolomide in diverse tumorsJoann P Palma, Yi-Chun Wang, Luis E Rodriguez, et al.
Journal of Medicinal Chemistry|January 16, 2009
Discovery of the Poly(ADP-ribose) polymerase (PARP) inhibitor 2-[(R)-2-methylpyrrolidin-2-yl]-1H-benzimidazole-4-carboxamide (ABT-888) for the treatment of cancerThomas D Penning, Gui-Dong Zhu, Viraj B Gandhi, et al.
Journal of Medicinal Chemistry|October 22, 2009
Discovery of 3H-benzo[4,5]thieno[3,2-d]pyrimidin-4-ones as potent, highly selective, and orally bioavailable inhibitors of the human protooncogene proviral insertion site in moloney murine leukemia virus (PIM) kinasesZhi-Fu Tao, Lisa A Hasvold, Joel D Leverson, et al.
Bioorganic & Medicinal Chemistry Letters|March 10, 2004
Synthesis of cinnamic acids and related isosteres as potent and selective alpha v beta 3 receptor antagonistsThomas D Penning, Mark A Russell, Barbara B Chen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 1, 2011
Iniparib nonselectively modifies cysteine-containing proteins in tumor cells and is not a bona fide PARP inhibitorXuesong Liu, Yan Shi, David X Maag, et al.
Journal of Medicinal Chemistry|November 6, 2009
Synthesis and evaluation of a new generation of orally efficacious benzimidazole-based poly(ADP-ribose) polymerase-1 (PARP-1) inhibitors as anticancer agentsYunsong Tong, Jennifer J Bouska, Paul A Ellis, et al.
Leukemia|December 13, 2019
A novel CDK9 inhibitor increases the efficacy of venetoclax (ABT-199) in multiple models of hematologic malignanciesDarren C Phillips, Sha Jin, Gareth P Gregory, et al.
Pageof 4

Showing results (11-20 of 34) with videos related to

Sort By:
Pageof 4
ACS Medicinal Chemistry Letters|January 16, 2015
Pyrimidine-based tricyclic molecules as potent and orally efficacious inhibitors of wee1 kinaseYunsong Tong, Maricel Torrent, Alan S Florjancic, et al.
Bioorganic & Medicinal Chemistry Letters|July 1, 2008
Synthesis and SAR of novel, potent and orally bioavailable benzimidazole inhibitors of poly(ADP-ribose) polymerase (PARP) with a quaternary methylene-amino substituentGui-Dong Zhu, Viraj B Gandhi, Jianchun Gong, et al.
Bioorganic & Medicinal Chemistry|July 7, 2012
Discovery and SAR of orally efficacious tetrahydropyridopyridazinone PARP inhibitors for the treatment of cancerGui-Dong Zhu, Jianchun Gong, Viraj B Gandhi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 26, 2009
ABT-888 confers broad in vivo activity in combination with temozolomide in diverse tumorsJoann P Palma, Yi-Chun Wang, Luis E Rodriguez, et al.
Journal of Medicinal Chemistry|January 16, 2009
Discovery of the Poly(ADP-ribose) polymerase (PARP) inhibitor 2-[(R)-2-methylpyrrolidin-2-yl]-1H-benzimidazole-4-carboxamide (ABT-888) for the treatment of cancerThomas D Penning, Gui-Dong Zhu, Viraj B Gandhi, et al.
Journal of Medicinal Chemistry|October 22, 2009
Discovery of 3H-benzo[4,5]thieno[3,2-d]pyrimidin-4-ones as potent, highly selective, and orally bioavailable inhibitors of the human protooncogene proviral insertion site in moloney murine leukemia virus (PIM) kinasesZhi-Fu Tao, Lisa A Hasvold, Joel D Leverson, et al.
Bioorganic & Medicinal Chemistry Letters|March 10, 2004
Synthesis of cinnamic acids and related isosteres as potent and selective alpha v beta 3 receptor antagonistsThomas D Penning, Mark A Russell, Barbara B Chen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 1, 2011
Iniparib nonselectively modifies cysteine-containing proteins in tumor cells and is not a bona fide PARP inhibitorXuesong Liu, Yan Shi, David X Maag, et al.
Journal of Medicinal Chemistry|November 6, 2009
Synthesis and evaluation of a new generation of orally efficacious benzimidazole-based poly(ADP-ribose) polymerase-1 (PARP-1) inhibitors as anticancer agentsYunsong Tong, Jennifer J Bouska, Paul A Ellis, et al.
Leukemia|December 13, 2019
A novel CDK9 inhibitor increases the efficacy of venetoclax (ABT-199) in multiple models of hematologic malignanciesDarren C Phillips, Sha Jin, Gareth P Gregory, et al.
Pageof 4